Cytek Biosciences（8EQ）株式概要Cytek Biosciences, Inc.は細胞解析ソリューション企業であり、生物医学研究や臨床応用における科学的進歩を促進する細胞解析ツールを提供している。 詳細8EQ ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析German市場と比較した過去 3 か月間の株価の変動現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見る8EQ Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€3.3438.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-74m282m2016201920222025202620282031Revenue US$282.3mEarnings US$36.1mAdvancedSet Fair ValueView all narrativesCytek Biosciences, Inc. 競合他社GerresheimerSymbol: XTRA:GXIMarket cap: €953.3mEvotecSymbol: XTRA:EVTMarket cap: €882.3mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €2.6bPExASymbol: DB:FA0Market cap: €30.5m価格と性能株価の高値、安値、推移の概要Cytek Biosciences過去の株価現在の株価US$3.3452週高値US$5.6052週安値US$2.18ベータ1.231ヶ月の変化-9.73%3ヶ月変化-9.24%1年変化49.11%3年間の変化-54.56%5年間の変化n/aIPOからの変化-83.71%最新ニュースNew Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Share price has been volatile over the past 3 months (8.8% average weekly change).お知らせ • Apr 30Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026.お知らせ • Apr 25Cytek Biosciences, Inc. to Report Q1, 2026 Results on May 07, 2026Cytek Biosciences, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Feb 27Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2026Cytek Biosciences, Inc. provided revenue guidance for the full year 2026. The company initiates its 2026 revenue guidance for full year 2026 revenue to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change in current foreign currency exchange rates or 2025 US tariff policy.お知らせ • Feb 13Cytek Biosciences, Inc. to Report Q4, 2025 Results on Feb 26, 2026Cytek Biosciences, Inc. announced that they will report Q4, 2025 results After-Market on Feb 26, 2026お知らせ • Jan 12Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025Cytek Biosciences, Inc. provides earnings guidance for the fourth quarter and full year 2025. For the quarter, the company expects total revenue for the full year 2025 to be approximately $201 million. For the quarter, the company expects revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025.最新情報をもっと見るRecent updatesNew Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Share price has been volatile over the past 3 months (8.8% average weekly change).お知らせ • Apr 30Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026.お知らせ • Apr 25Cytek Biosciences, Inc. to Report Q1, 2026 Results on May 07, 2026Cytek Biosciences, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Feb 27Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2026Cytek Biosciences, Inc. provided revenue guidance for the full year 2026. The company initiates its 2026 revenue guidance for full year 2026 revenue to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change in current foreign currency exchange rates or 2025 US tariff policy.お知らせ • Feb 13Cytek Biosciences, Inc. to Report Q4, 2025 Results on Feb 26, 2026Cytek Biosciences, Inc. announced that they will report Q4, 2025 results After-Market on Feb 26, 2026お知らせ • Jan 12Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025Cytek Biosciences, Inc. provides earnings guidance for the fourth quarter and full year 2025. For the quarter, the company expects total revenue for the full year 2025 to be approximately $201 million. For the quarter, the company expects revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025.お知らせ • Nov 07Cytek Biosciences, Inc. Reaafirms Earnings Guidance for the Full Year 2025Cytek Biosciences, Inc. reaafirmed earnings guidance for the full year 2025. For the period, Company expects revenue to be in the range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024, assuming no change from current currency exchange rates.お知らせ • Oct 23Cytek Biosciences, Inc. to Report Q3, 2025 Results on Nov 05, 2025Cytek Biosciences, Inc. announced that they will report Q3, 2025 results on Nov 05, 2025お知らせ • Sep 12Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences Iccs and EsccaCytek Biosciences, Inc. will showcase its advanced, high-parameter solutions at two notable industry events later this month: the European Society for Clinical Cell Analysis (ESCCA) 2025 Conference and ICCS 2025, the 40th Annual International Clinical Cytometry Meeting & Course. Set apart from traditional flow cytometry approaches, Cytek's distinctive Full Spectrum Profiling™? (FSP®?) technology has profoundly changed the understanding of cell biology, immunology, oncology, and targeted therapeutic methodologies - leading to streamlined workflows, accelerated discovery, and enhanced efficiency. The company's FSP systems have become the spectral technology of choice for researchers worldwide, with more than 2,800 peer-reviewed publications citing their use. ESCCA 2025 will be held in Montpellier, France, from September 17, 2025 through September 20, 2025, and will attract a global audience of clinicians and researchers. At the conference, Cytek will showcase its comprehensive end-to-end cell analysis solutions, designed to empower clinicians and researchers with deeper scientific insights, enable faster data-driven decision-making, and drive accelerated innovation. Additionally, Joseph C. Lownik, M.D., Ph.D., hematopathologist in the Department of Pathology & Laboratory Medicine at Cedars-Sinai, will conduct a workshop titled, "Pairing of Spectral Flow Cytometry and Machine Learning Based Decision Support System for Accurate Diagnosis of Leukemia and Lymphoma." Taking place on September 19, 2025, from 12:15 - 12:45 p.m. in the Pasteur Room, Dr. Lownik's presentation of his work will explore how integrating high-parameter spectral flow cytometry with machine learning based clinical decision support can simplify data analysis and reduce technician workload.お知らせ • Aug 07Cytek Biosciences Narrows Earnings Guidance for the Full Year 2025Cytek Biosciences narrowed earnings guidance for the full year 2025. For the full year, the company expects revenue to be in the range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024, assuming no change from current currency exchange rates.お知らせ • Jul 24Cytek Biosciences, Inc. to Report Q2, 2025 Results on Aug 06, 2025Cytek Biosciences, Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 06, 2025お知らせ • May 30Cytek Biosciences, Inc. Announces the Launch of the Cytek Aurora Evo SystemCytek Biosciences, Inc. announced the launch of the Cytek Aurora™? Evo system, a new full spectrum flow cytometer that improves on its Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™? (FSP®?) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use - more than any other spectral flow cytometer. Building on this success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek AuroraEvo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 uL/min) to max (200 uL/min). Samples can now be acquired 2x faster than before. Small Particle Detection: Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora EvO flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. The Cytek Aurora Eva Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth.お知らせ • May 09Cytek Biosciences, Inc. Revises Revenue Guidance for the Full Year 2025Cytek Biosciences, Inc. revised revenue guidance for the full year 2025. For the period, Company expects revenue to be in the range of $196 million to $210 million, representing growth of -2% to 5% over full year 2024, assuming no change in currency exchange rates.お知らせ • Apr 30Cytek Biosciences, Inc., Annual General Meeting, Jun 18, 2025Cytek Biosciences, Inc., Annual General Meeting, Jun 18, 2025.お知らせ • Apr 25Cytek Biosciences, Inc. to Report Q1, 2025 Results on May 08, 2025Cytek Biosciences, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025お知らせ • Mar 19Cytek Biosciences, Inc. Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek Muse Micro SystemCytek Biosciences, Inc. announced that it has added transformative capabilities to its iconic Cytek Guava Muse cell analyzer, creating a next-generation instrument called the Cytek Muse Micro. The Muse Micro cell analyzer is an affordable option that simplifies flow cytometry while enhancing ease-of-use, precision and versatility. The Muse Micro system expands assay capabilities to penetrate established and emerging markets such as cell and gene therapy, drug discovery, pathway analysis, cell counting, viability, apoptosis, cellular stress and immune cell monitoring. ophisticated cell analysis is no longer exclusive, complex, or expensive. Its intuitive touchscreen interface, easy-to-use software, and optimized "Mix-and-Read" assays combine to streamline and simplify flow cytometry analyses. The Muse Micro cell analyzer is built on the legacy of the original Muse system - which was introduced in 2013 as the most compact flow cytometer the world had ever seen. The original Muse system has an extensive worldwide installed base and has been featured in thousands of publications since its inception. The new Muse Micro system is equipped with a 488 nm blue laser and offers five parameters, including forward and side scatter alongside three fluorescent channels. Its intuitive software interface and pre-optimized assay kits make routine assays - including cell count, viability, health, stress and population identification analyses - faster and more accessible than ever before. Cytek anticipates that the Muse Micro system will sustain the growth of the Muse reagent business by utilizing additional new channels. Advanced microcapillary technology: A high-precision displacement pump delivers accurate and precise cell counts, eliminating the need for calibration beads. Pre-optimized kits and modules: Streamlines routine assays with reliable, reproducible results and minimal setup time with additional kits in development. Simplified data acquisition and analysis: Includes Cytek InCyte software, empowering users to develop and run their own three-color assays. Affordable: Provides reliable flow cytometry analysis at a cost-effective price point, making it accessible to every lab.お知らせ • Feb 28Cytek Biosciences Provides Earnings Guidance for the Year Ended December 31, 2025Cytek Biosciences expects total revenue for the year ended December 31, 2025 to be in the range of $204 million to $212 million, representing growth of 2% to 6% over the year ended December 31, 2024, assuming no change in currency exchange rates.お知らせ • Feb 14Cytek Biosciences, Inc. to Report Q4, 2024 Results on Feb 27, 2025Cytek Biosciences, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 27, 2025お知らせ • Jan 16Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024Cytek Biosciences, Inc. provided earnings guidance for the fourth quarter and full year of 2024. The company expects fourth quarter revenue of $57 million to $58 million represents growth of 11% to 13% compared to the third quarter of 2024 and decline of 2% to flat compared to a strong fourth quarter of 2023. The appreciation of the US dollar negatively affected fourth quarter revenue by approximately $1.5 million. The company expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek’s 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million.お知らせ • Jan 01Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The repurchase program is valid till December 31, 2025.お知らせ • Nov 08Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs SystemCytek Biosciences, Inc. has introduced an Enhanced Small Particle (ESP) Detection Option for its Cytek Aurora CS system. This is the first commercially available small particle detector on a cell sorter and offers a significant advancement for rapidly evolving research fields, including in drug delivery, cell therapy, disease diagnostics, circulating tumor cells, regenerative medicine, and vaccine delivery. Researchers can now achieve downstream analysis of materials that were previously unable to be sorted, opening new possibilities for breakthroughs in these areas. Once regarded as cellular debris, exosomes and extracellular vesicles (EVs) are now recognized as pivotal to cell-to-cell communication, disease progression, and therapeutic delivery. With the surge in research interest driven by technological innovations, EVs have become central to a growing body of scientific publications and clinical trials. With Cytek's ESP Detection Option, particles as small as 70 nm can now be studied and sorted for downstream analysis, giving researchers the ability to characterize the full emission spectra of small particles. The Cytek Aurora CS system builds on Cytek’s established Full Spectrum Profiling (FSP) technology, known for its ability to resolve and sort even the most complex cell populations with unmatched sensitivity. The system enables seamless assay transfer from analyzer to sorter, without the need to redesign panels or reconfigure detectors, allowing researchers to isolate and study identical cell populations. It also supports downstream applications such as single-cell RNA sequencing, proteomics, and cell biology, making it a versatile tool for researchers who need both flexibility and precision. Furthermore, assays designed on conventional flow cytometers can easily be run on the Cytek Aurora CS system, minimizing disruption while maximizing productivity.New Risk • Nov 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 07Third quarter 2024 earnings released: EPS: US$0.007 (vs US$0.047 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.007 (up from US$0.047 loss in 3Q 2023). Revenue: US$51.5m (up 7.3% from 3Q 2023). Net income: US$941.0k (up US$7.40m from 3Q 2023). Profit margin: 1.8% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.お知らせ • Nov 06Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024Cytek Biosciences, Inc. reaffirmed earnings guidance for the year 2024. The company reaffirms its 2024 revenue guidance of full year 2024 revenue to be in the range of $203 million to $210 million, representing growth of 5% to 9% over full year 2023, assuming no change in currency exchange rates. In addition, the company continues to expect to report a net loss in the single digit millions for the full year 2024.お知らせ • Oct 30Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024Cytek Biosciences, Inc. announced that they will report Q3, 2024 results After-Market on Nov 05, 2024お知らせ • Sep 12Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024Cytek Biosciences, Inc. announced that on September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of the company, effective as of September 27, 2024, to pursue another career opportunity.Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.079 loss per share (vs US$0.032 loss in 2Q 2023)Second quarter 2024 results: US$0.079 loss per share (further deteriorated from US$0.032 loss in 2Q 2023). Revenue: US$46.6m (down 6.2% from 2Q 2023). Net loss: US$10.4m (loss widened 138% from 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.お知らせ • Aug 07Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024Cytek Biosciences, Inc. narrowed earnings guidance for the year 2024. The company narrowed the range of its 2024 revenue guidance, now expecting full year 2024 revenue to in the range of $203 million to $210 million, representing growth of 5% to 9% over full year 2023, assuming no change in currency exchange rates. In addition, Cytek expects to report a net loss in the single digit millions for the full year 2024 due to an outlook of slightly lower gross profit, higher than expected stock-based compensation, and lower other income.お知らせ • Jul 31+ 1 more updateCytek Biosciences, Inc. Automates Panel Design with New Intelligent AlgorithmCytek Biosciences, Inc. announced that it has developed a revolutionary tool to automate panel design. The company has expanded the capabilities of the Panel Builder tool within its Cytek® Cloud digital ecosystem with the addition of SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes. Optimized for Cytek’s Full Spectrum Profiling™ (FSP™) technology, the SpectroPanel tool automates the assignment of fluorochromes to markers, removing the labor-intensive manual process. This allows scientists to jumpstart their panel design process. With over 11,000 users and counting, Cytek Cloud is a vital resource in the research community. Supporting full spectrum flow cytometry research from panel design to experiment setup to data acquisition, Cytek Cloud enables researchers to design panels with ease, taking into account antigen density, marker expression, and reagent availability. Users can also access Cytek cFluor® and Tonbo™ reagents within the platform, via built-in Cytek and partner catalogs. Cytek Cloud consists of a suite of integrated, online software tools that streamline workflows – combining all spectral panel design tools in one place and allowing users to prepare experiments remotely. Cytek Cloud accelerates the time to insight for a wide range of applications, including immunology, oncology, infectious diseases, and inflammatory diseases. The Panel Builder tool features an easy-to-use panel wizard that guides panel design with the ability to search and modify pre-designed panels and Optimized Multicolor Immunofluorescence Panels (OMIPs). Users can easily build and share panels.お知らせ • Jun 08Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The repurchase program is valid till December 31, 2024.お知らせ • May 10Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024Cytek Biosciences reaffirms its 2024 revenue guidance, expecting full year 2024 revenue in the range of $203 million to $213 million, representing growth of 5% to 10% over full year 2023, assuming no change in currency exchange rates. For the year ending December 31, 2024, Cytek Biosciences expects to report positive net income.お知らせ • May 01Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024Cytek Biosciences, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024お知らせ • Apr 28Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024, at 11:00 Pacific Standard Time. Agenda: To elect two Class III directors, Wenbin Jiang, Ph.D. and Michael Holder, each to serve a three-year term expiring at our 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal; to vote, on an advisory basis, regarding the compensation of named executive officers for the year ended December 31, 2023; to ratify the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.お知らせ • Mar 19+ 1 more updateCytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development AnalyticsCytek Biosciences, Inc. announced that Patrik Jeanmonod has been appointed as the company’s head of corporate development analytics. Jeanmonod served as Cytek’s chief financial officer since 2018.お知らせ • Mar 03Cytek Biosciences, Inc. announced delayed annual 10-K filingOn 03/01/2024, Cytek Biosciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 01Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024Cytek Biosciences, Inc. provided earnings guidance for the year ended December 31, 2024. For the period, the company expects total revenue to be in the range of $203 million to $213 million, representing growth of 5% to 10% over the year ended December 31, 2023, assuming no change in currency exchange rates. Also, the company expects to report positive net income.お知らせ • Feb 08Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024Cytek Biosciences, Inc. announced that they will report Q4, 2023 results After-Market on Feb 28, 2024お知らせ • Jan 08Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023Cytek Biosciences, Inc. provided revenue guidance for the year 2023. For the year, the company expects revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million, provided on November 9, 2023.お知らせ • Dec 21Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow CytometryCytek Biosciences, Inc. announced the introduction of the Cytek Orion™ reagent cocktail preparation system. Cytek’s new automated reagent cocktailing technology simplifies and accelerates laboratory workflow, assures consistent experimental results, saves time and reduces the potential for errors. Manually preparing reagent cocktails for flow cytometry can be a time-consuming, error-prone process, particularly when panels with more than six colors are being used. The Cytek Orion system, a small, easy-to-operate, fully automated reagent cocktail preparation instrument for flow cytometry, eliminates the need for lab technicians to manually prepare multicolor antibody cocktails for flow cytometry. With the Cytek Orion system, users can mix and manage reagent cocktail combinations of up to 60 individual reagent antibody conjugates. The Cytek Orion workflow is designed to fit seamlessly with the Cytek ecosystem of complete solutions – including its cloud-based platform, analyzers, sorter, reagents, and software. It is instrument agnostic, enabling it to be used with other systems as well. Key features include: Accommodates antibody-conjugate tubes with volumes of 0.5 mL to 2.0 mL per tube, Up to 60 individual reagents can be added per cocktail, Aspirator can add 4 uL to 200 uL of reagent to cocktail at the proper volume and concentration, SpectroPrep™ software stores information regarding reagents in a library for future use and can provide an audit trail, Users can mix up to three different reagent cocktails per run, Users can create cocktail recipes and save for reuse, or use pre-programmed recipes for Cytek kits and assays. Key benefits include: Hands-on time savings in the lab due to walk away automation, Reduces costs due to potential human errors in cocktail preparation, Decrease in repetitive motion injuries when preparing high-color assays.お知らせ • Nov 15Cytek Biosciences, Inc. announced delayed 10-Q filingOn 11/13/2023, Cytek Biosciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Nov 10Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.012 profit in 3Q 2022)Third quarter 2023 results: US$0.047 loss per share (down from US$0.012 profit in 3Q 2022). Revenue: US$48.0m (up 19% from 3Q 2022). Net loss: US$6.46m (down 488% from profit in 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 08Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023Cytek Biosciences, Inc. provided revenue guidance for the year 2023. The company expects full year 2023 total revenue to be in the range of $188 million to $192 million, representing growth of 15% to 17% over full year 2022. This includes an expected revenue contribution from organic business to be approximately flat versus 2022 and inorganic revenue in the range of $25 million to $30 million from the Luminex flow cytometry and imaging business, which was acquired on February 28, 2023.お知らせ • Oct 20Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023Cytek Biosciences, Inc. announced that they will report Q3, 2023 results After-Market on Nov 07, 2023New Risk • Oct 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Aug 29Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & ServicesCytek Biosciences, Inc. announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. Cytek’s acquisition of the Amnis and Guava product lines from Luminex Corporation in February 2023 provided the Company with expanded market access, new product development opportunities, and operational synergies. To take advantage of these expanded market and product development opportunities, Cytek is reorganizing its Commercial function into two distinct operations: the enhanced sales organization led by Dr. Busque, and a new Platform organization, which will encompass marketing, product roadmaps, and program management. The Company believes the new structure will support the Company’s transition toward a market-driven organization and to develop and sell cell analysis solutions based on market-derived inputs. These market inputs will shape Cytek’s research, new product, and applications development, and its approach to interacting with customers.Reported Earnings • Aug 09Second quarter 2023 earnings released: US$0.032 loss per share (vs US$0.004 loss in 2Q 2022)Second quarter 2023 results: US$0.032 loss per share (further deteriorated from US$0.004 loss in 2Q 2022). Revenue: US$49.7m (up 24% from 2Q 2022). Net loss: US$4.39m (loss widened US$3.79m from 2Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Aug 09Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023Cytek Biosciences, Inc. provided revenue guidance for the full year 2023. For the period, the company expects total revenue to be in the range of $205 million to $220 million, representing growth of 25% to 34% over full year 2022. This includes an expected revenue contribution in the range of $180 million to $190 million from its existing organic business and in the range of $25 million to $30 million from the acquired Luminex flow cytometry and imaging business, which closed on February 28, 2023.お知らせ • Jul 23Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023Cytek Biosciences, Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023お知らせ • May 20Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The repurchase program will continue until the end of the fiscal year unless extended or shortened by the Board of Directors.Reported Earnings • May 11First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.015 loss in 1Q 2022)First quarter 2023 results: US$0.05 loss per share (further deteriorated from US$0.015 loss in 1Q 2022). Revenue: US$37.1m (up 5.8% from 1Q 2022). Net loss: US$6.81m (loss widened 237% from 1Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • May 10Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023Cytek Biosciences, Inc. revised earnings guidance for the year 2023. The company has revised its full year 2023 revenue outlook and now expects total revenue to be in the range of $205 million to $220 million, representing growth of 25% to 34% over full year 2022. This includes an expected revenue contribution in the range of $25 million to $30 million from the acquisition of Luminex’s flow cytometry and imaging business, which closed on February 28, 2023.Reported Earnings • Mar 02Full year 2022 earnings released: EPS: US$0.018 (vs US$0.001 in FY 2021)Full year 2022 results: EPS: US$0.018 (up from US$0.001 in FY 2021). Revenue: US$164.0m (up 28% from FY 2021). Net income: US$2.39m (up US$2.34m from FY 2021). Profit margin: 1.5% (up from 0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 14Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million.Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million on February 13, 2023. The sale is expected to close within 30 days, subject to customary closing conditions.お知らせ • Feb 08Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023Cytek Biosciences, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 28, 2023お知らせ • Nov 16Cytek Biosciences, Inc. Introduces Cytek CloudCytek Biosciences, Inc. announced the launch of Cytek Cloud – a cloud-based platform that features two integrated tools to streamline workflows on Cytek’s cell sorters and analyzers. Optimized for Cytek systems and reagents, Cytek Cloud joins the company’s extensive suite of solutions for the single cell analysis market, which includes the incorporation of Full Spectrum Profiling (FSP) technology onboard its flow cytometry systems, proprietary cFluor reagents, and SpectroFlo software. The new Cytek Cloud digital ecosystem combines all of Cytek’s spectral panel design tools in one place and allows users to prepare experiments remotely prior to accessing the instrument. The benefit in this approach is accelerating the time to insight for a wide range of applications including immunology, oncology, infectious diseases, and inflammatory diseases.Reported Earnings • Nov 11Third quarter 2022 earnings released: EPS: US$0.012 (vs US$0.003 in 3Q 2021)Third quarter 2022 results: EPS: US$0.012 (up from US$0.003 in 3Q 2021). Revenue: US$40.5m (up 18% from 3Q 2021). Net income: US$1.67m (up 382% from 3Q 2021). Profit margin: 4.1% (up from 1.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 10Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022Cytek Biosciences announced that the company continues to expect full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.お知らせ • Nov 01Cytek Biosciences, Inc. Names Chris Williams Chief Operating OfficerCytek Biosciences, Inc. announced that Chris Williams has been appointed chief operating officer for the company. In this role, Williams will lead and execute the company’s global operations strategy to scale up its capability to support its mission as a full solution provider to its customers. Williams’ appointment is effective immediately, reporting directly to Dr. Wenbin Jiang, chairman and CEO of Cytek Biosciences. Prior to joining Cytek, Williams served as vice president of engineering, technology, operations and innovation for Thermo Fisher’s Pharma Services Group. Before that, he was vice president and general manager for single use technologies and vice president and general manager for bioprocess equipment and automation – both at Thermo Fisher Scientific. He also served as vice president of site engineering for Bayer Pharmaceuticals Division. Williams holds a Bachelor of Science degree in Mechanical Engineering from the University of Texas at Austin.お知らせ • Oct 27Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022Cytek Biosciences, Inc. announced that they will report Q3, 2022 results After-Market on Nov 09, 2022Reported Earnings • Aug 12Second quarter 2022 earnings releasedSecond quarter 2022 results: US$0.004 loss per share. Revenue: US$40.2m (up 32% from 2Q 2021). Net loss: US$598.0k (flat on 2Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 13% growth forecast for the industry in Germany.お知らせ • Aug 11Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022Cytek Biosciences, Inc. provided earnings guidance for the full year 2022. For the period, Company expects revenue to be closer to the high end of the range of $160 million to $168 million.お知らせ • Jul 21Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022Cytek Biosciences, Inc. announced that they will report Q2, 2022 results After-Market on Aug 10, 2022お知らせ • Jun 26Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value IndexCytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Indexお知らせ • Jun 24Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022Cytek Biosciences, Inc. reaffirmed earning guidance for 2022. Revenue guidance closer to the higher of the range of $160 million to $168 million.お知らせ • Jun 07Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I DirectorOn June 1, 2022, Cytek Biosciences, Inc. held its 2022 annual meeting of stockholders, elected Deborah Neff, Don Hardison as Class I director.Reported Earnings • May 13First quarter 2022 earnings releasedFirst quarter 2022 results: US$0.015 loss per share. Revenue: US$35.1m (up 45% from 1Q 2021). Net loss: US$2.02m (flat on 1Q 2021). Over the next year, revenue is forecast to grow 29%, compared to a 13% growth forecast for the industry in Germany.お知らせ • May 12Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022Cytek Biosciences, Inc. provided revenue guidance for the full year 2022. The company expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.お知らせ • Apr 15Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022, at 11:00 Pacific Standard Time. Agenda: To elect each of the company's two nominees, Deborah Neff and Don Hardison, to the company's board of directors for a three-year term, to hold office until the company's 2025 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal; to ratify the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2022; and to conduct any other business properly brought before the meeting.Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: US$0.001 (down from US$0.11 in FY 2020). Revenue: US$128.0m (up 38% from FY 2020). Net income: US$52.0k (down 98% from FY 2020). Profit margin: 0% (down from 3.5% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 28%, compared to a 24% growth forecast for the pharmaceuticals industry in Germany.お知らせ • Feb 24Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022Cytek Biosciences, Inc. provided revenue guidance for the fiscal year 2022. Cytek Biosciences expects full year 2022 revenue to be in the range of $160 million to $168 million.お知らせ • Feb 12Cytek Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022Cytek Biosciences, Inc. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022株主還元8EQDE Life SciencesDE 市場7D10.6%3.5%1.6%1Y49.1%-10.5%2.2%株主還元を見る業界別リターン: 8EQ過去 1 年間で-10.5 % の収益を上げたGerman Life Sciences業界を上回りました。リターン対市場: 8EQ過去 1 年間で2.2 % の収益を上げたGerman市場を上回りました。価格変動Is 8EQ's price volatile compared to industry and market?8EQ volatility8EQ Average Weekly Movement9.0%Life Sciences Industry Average Movement9.1%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: 8EQの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 8EQの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1992678Wenbin Jiangcytekbio.com細胞分析ソリューション企業であるCytek Biosciences, Inc.は、生物医学研究と臨床応用における科学的進歩を促進する細胞分析ツールを提供している。同社は、細胞分析を提供するオーロラシステムとノーザンライトシステム、フルスペクトラムのプロファイリング技術を活用し、細胞分析における潜在的なアプリケーションをさらに広げるオーロラセルソーターシステム、強化された小粒子検出、アムニスイメージストリームイメージングフローサイトメーター、グアバミューズセルアナライザー、グアバイージーサイトフローサイトメーター、オリオン試薬カクテル調製システムを提供している。cFluor試薬を含む試薬やキットも提供している。cFluor試薬は、蛍光色素を結合させた抗体で、同社の装置で分析する目的の細胞を同定するために使用される。さらに、自動マイクロサンプリングシステムと自動サンプルローダーシステム、オーロラシステムとノーザンライトシステムにシームレスに統合するように設計された自動ローダー、オーロラシステムとノーザンライトシステムの品質管理からデータ解析までの直感的なワークフローを提供するSpectroFloソフトウェア、カスタマーサポートツールも提供している。製薬会社、バイオ製薬会社、学術研究センター、臨床研究機関を顧客としている。北米、欧州、中国、アジア太平洋地域では直販組織とサポート組織を通じて、欧州、中南米、中東諸国ではディストリビューターや販売代理店を通じて製品を販売している。同社は以前はサイトビル社として知られていたが、2015年8月に社名をサイテック・バイオサイエンシズ社に変更した。サイテック・バイオサイエンシズ・インクは1992年に設立され、カリフォルニア州フリーモントに本社を置いている。もっと見るCytek Biosciences, Inc. 基礎のまとめCytek Biosciences の収益と売上を時価総額と比較するとどうか。8EQ 基礎統計学時価総額€440.92m収益（TTM）-€63.64m売上高(TTM)€175.59m2.5xP/Sレシオ-7.0xPER（株価収益率8EQ は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計8EQ 損益計算書（TTM）収益US$204.17m売上原価US$98.61m売上総利益US$105.56mその他の費用US$179.56m収益-US$74.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.57グロス・マージン51.70%純利益率-36.25%有利子負債／自己資本比率3.4%8EQ の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 19:43終値2026/05/27 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cytek Biosciences, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Kyle MiksonCanaccord GenuityMatthew SykesGoldman SachsKallum TitchmarshMorgan Stanley6 その他のアナリストを表示
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Share price has been volatile over the past 3 months (8.8% average weekly change).
お知らせ • Apr 30Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026.
お知らせ • Apr 25Cytek Biosciences, Inc. to Report Q1, 2026 Results on May 07, 2026Cytek Biosciences, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Feb 27Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2026Cytek Biosciences, Inc. provided revenue guidance for the full year 2026. The company initiates its 2026 revenue guidance for full year 2026 revenue to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change in current foreign currency exchange rates or 2025 US tariff policy.
お知らせ • Feb 13Cytek Biosciences, Inc. to Report Q4, 2025 Results on Feb 26, 2026Cytek Biosciences, Inc. announced that they will report Q4, 2025 results After-Market on Feb 26, 2026
お知らせ • Jan 12Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025Cytek Biosciences, Inc. provides earnings guidance for the fourth quarter and full year 2025. For the quarter, the company expects total revenue for the full year 2025 to be approximately $201 million. For the quarter, the company expects revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025.
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Share price has been volatile over the past 3 months (8.8% average weekly change).
お知らせ • Apr 30Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026Cytek Biosciences, Inc., Annual General Meeting, Jun 10, 2026.
お知らせ • Apr 25Cytek Biosciences, Inc. to Report Q1, 2026 Results on May 07, 2026Cytek Biosciences, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Feb 27Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2026Cytek Biosciences, Inc. provided revenue guidance for the full year 2026. The company initiates its 2026 revenue guidance for full year 2026 revenue to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change in current foreign currency exchange rates or 2025 US tariff policy.
お知らせ • Feb 13Cytek Biosciences, Inc. to Report Q4, 2025 Results on Feb 26, 2026Cytek Biosciences, Inc. announced that they will report Q4, 2025 results After-Market on Feb 26, 2026
お知らせ • Jan 12Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025Cytek Biosciences, Inc. provides earnings guidance for the fourth quarter and full year 2025. For the quarter, the company expects total revenue for the full year 2025 to be approximately $201 million. For the quarter, the company expects revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025.
お知らせ • Nov 07Cytek Biosciences, Inc. Reaafirms Earnings Guidance for the Full Year 2025Cytek Biosciences, Inc. reaafirmed earnings guidance for the full year 2025. For the period, Company expects revenue to be in the range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024, assuming no change from current currency exchange rates.
お知らせ • Oct 23Cytek Biosciences, Inc. to Report Q3, 2025 Results on Nov 05, 2025Cytek Biosciences, Inc. announced that they will report Q3, 2025 results on Nov 05, 2025
お知らせ • Sep 12Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences Iccs and EsccaCytek Biosciences, Inc. will showcase its advanced, high-parameter solutions at two notable industry events later this month: the European Society for Clinical Cell Analysis (ESCCA) 2025 Conference and ICCS 2025, the 40th Annual International Clinical Cytometry Meeting & Course. Set apart from traditional flow cytometry approaches, Cytek's distinctive Full Spectrum Profiling™? (FSP®?) technology has profoundly changed the understanding of cell biology, immunology, oncology, and targeted therapeutic methodologies - leading to streamlined workflows, accelerated discovery, and enhanced efficiency. The company's FSP systems have become the spectral technology of choice for researchers worldwide, with more than 2,800 peer-reviewed publications citing their use. ESCCA 2025 will be held in Montpellier, France, from September 17, 2025 through September 20, 2025, and will attract a global audience of clinicians and researchers. At the conference, Cytek will showcase its comprehensive end-to-end cell analysis solutions, designed to empower clinicians and researchers with deeper scientific insights, enable faster data-driven decision-making, and drive accelerated innovation. Additionally, Joseph C. Lownik, M.D., Ph.D., hematopathologist in the Department of Pathology & Laboratory Medicine at Cedars-Sinai, will conduct a workshop titled, "Pairing of Spectral Flow Cytometry and Machine Learning Based Decision Support System for Accurate Diagnosis of Leukemia and Lymphoma." Taking place on September 19, 2025, from 12:15 - 12:45 p.m. in the Pasteur Room, Dr. Lownik's presentation of his work will explore how integrating high-parameter spectral flow cytometry with machine learning based clinical decision support can simplify data analysis and reduce technician workload.
お知らせ • Aug 07Cytek Biosciences Narrows Earnings Guidance for the Full Year 2025Cytek Biosciences narrowed earnings guidance for the full year 2025. For the full year, the company expects revenue to be in the range of $196 million to $205 million, representing growth of -2% to +2% over full year 2024, assuming no change from current currency exchange rates.
お知らせ • Jul 24Cytek Biosciences, Inc. to Report Q2, 2025 Results on Aug 06, 2025Cytek Biosciences, Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 06, 2025
お知らせ • May 30Cytek Biosciences, Inc. Announces the Launch of the Cytek Aurora Evo SystemCytek Biosciences, Inc. announced the launch of the Cytek Aurora™? Evo system, a new full spectrum flow cytometer that improves on its Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™? (FSP®?) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use - more than any other spectral flow cytometer. Building on this success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek AuroraEvo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 uL/min) to max (200 uL/min). Samples can now be acquired 2x faster than before. Small Particle Detection: Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora EvO flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. The Cytek Aurora Eva Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth.
お知らせ • May 09Cytek Biosciences, Inc. Revises Revenue Guidance for the Full Year 2025Cytek Biosciences, Inc. revised revenue guidance for the full year 2025. For the period, Company expects revenue to be in the range of $196 million to $210 million, representing growth of -2% to 5% over full year 2024, assuming no change in currency exchange rates.
お知らせ • Apr 30Cytek Biosciences, Inc., Annual General Meeting, Jun 18, 2025Cytek Biosciences, Inc., Annual General Meeting, Jun 18, 2025.
お知らせ • Apr 25Cytek Biosciences, Inc. to Report Q1, 2025 Results on May 08, 2025Cytek Biosciences, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
お知らせ • Mar 19Cytek Biosciences, Inc. Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek Muse Micro SystemCytek Biosciences, Inc. announced that it has added transformative capabilities to its iconic Cytek Guava Muse cell analyzer, creating a next-generation instrument called the Cytek Muse Micro. The Muse Micro cell analyzer is an affordable option that simplifies flow cytometry while enhancing ease-of-use, precision and versatility. The Muse Micro system expands assay capabilities to penetrate established and emerging markets such as cell and gene therapy, drug discovery, pathway analysis, cell counting, viability, apoptosis, cellular stress and immune cell monitoring. ophisticated cell analysis is no longer exclusive, complex, or expensive. Its intuitive touchscreen interface, easy-to-use software, and optimized "Mix-and-Read" assays combine to streamline and simplify flow cytometry analyses. The Muse Micro cell analyzer is built on the legacy of the original Muse system - which was introduced in 2013 as the most compact flow cytometer the world had ever seen. The original Muse system has an extensive worldwide installed base and has been featured in thousands of publications since its inception. The new Muse Micro system is equipped with a 488 nm blue laser and offers five parameters, including forward and side scatter alongside three fluorescent channels. Its intuitive software interface and pre-optimized assay kits make routine assays - including cell count, viability, health, stress and population identification analyses - faster and more accessible than ever before. Cytek anticipates that the Muse Micro system will sustain the growth of the Muse reagent business by utilizing additional new channels. Advanced microcapillary technology: A high-precision displacement pump delivers accurate and precise cell counts, eliminating the need for calibration beads. Pre-optimized kits and modules: Streamlines routine assays with reliable, reproducible results and minimal setup time with additional kits in development. Simplified data acquisition and analysis: Includes Cytek InCyte software, empowering users to develop and run their own three-color assays. Affordable: Provides reliable flow cytometry analysis at a cost-effective price point, making it accessible to every lab.
お知らせ • Feb 28Cytek Biosciences Provides Earnings Guidance for the Year Ended December 31, 2025Cytek Biosciences expects total revenue for the year ended December 31, 2025 to be in the range of $204 million to $212 million, representing growth of 2% to 6% over the year ended December 31, 2024, assuming no change in currency exchange rates.
お知らせ • Feb 14Cytek Biosciences, Inc. to Report Q4, 2024 Results on Feb 27, 2025Cytek Biosciences, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 27, 2025
お知らせ • Jan 16Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024Cytek Biosciences, Inc. provided earnings guidance for the fourth quarter and full year of 2024. The company expects fourth quarter revenue of $57 million to $58 million represents growth of 11% to 13% compared to the third quarter of 2024 and decline of 2% to flat compared to a strong fourth quarter of 2023. The appreciation of the US dollar negatively affected fourth quarter revenue by approximately $1.5 million. The company expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek’s 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million.
お知らせ • Jan 01Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The repurchase program is valid till December 31, 2025.
お知らせ • Nov 08Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs SystemCytek Biosciences, Inc. has introduced an Enhanced Small Particle (ESP) Detection Option for its Cytek Aurora CS system. This is the first commercially available small particle detector on a cell sorter and offers a significant advancement for rapidly evolving research fields, including in drug delivery, cell therapy, disease diagnostics, circulating tumor cells, regenerative medicine, and vaccine delivery. Researchers can now achieve downstream analysis of materials that were previously unable to be sorted, opening new possibilities for breakthroughs in these areas. Once regarded as cellular debris, exosomes and extracellular vesicles (EVs) are now recognized as pivotal to cell-to-cell communication, disease progression, and therapeutic delivery. With the surge in research interest driven by technological innovations, EVs have become central to a growing body of scientific publications and clinical trials. With Cytek's ESP Detection Option, particles as small as 70 nm can now be studied and sorted for downstream analysis, giving researchers the ability to characterize the full emission spectra of small particles. The Cytek Aurora CS system builds on Cytek’s established Full Spectrum Profiling (FSP) technology, known for its ability to resolve and sort even the most complex cell populations with unmatched sensitivity. The system enables seamless assay transfer from analyzer to sorter, without the need to redesign panels or reconfigure detectors, allowing researchers to isolate and study identical cell populations. It also supports downstream applications such as single-cell RNA sequencing, proteomics, and cell biology, making it a versatile tool for researchers who need both flexibility and precision. Furthermore, assays designed on conventional flow cytometers can easily be run on the Cytek Aurora CS system, minimizing disruption while maximizing productivity.
New Risk • Nov 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 07Third quarter 2024 earnings released: EPS: US$0.007 (vs US$0.047 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.007 (up from US$0.047 loss in 3Q 2023). Revenue: US$51.5m (up 7.3% from 3Q 2023). Net income: US$941.0k (up US$7.40m from 3Q 2023). Profit margin: 1.8% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 06Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024Cytek Biosciences, Inc. reaffirmed earnings guidance for the year 2024. The company reaffirms its 2024 revenue guidance of full year 2024 revenue to be in the range of $203 million to $210 million, representing growth of 5% to 9% over full year 2023, assuming no change in currency exchange rates. In addition, the company continues to expect to report a net loss in the single digit millions for the full year 2024.
お知らせ • Oct 30Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024Cytek Biosciences, Inc. announced that they will report Q3, 2024 results After-Market on Nov 05, 2024
お知らせ • Sep 12Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024Cytek Biosciences, Inc. announced that on September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of the company, effective as of September 27, 2024, to pursue another career opportunity.
Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.079 loss per share (vs US$0.032 loss in 2Q 2023)Second quarter 2024 results: US$0.079 loss per share (further deteriorated from US$0.032 loss in 2Q 2023). Revenue: US$46.6m (down 6.2% from 2Q 2023). Net loss: US$10.4m (loss widened 138% from 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 07Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024Cytek Biosciences, Inc. narrowed earnings guidance for the year 2024. The company narrowed the range of its 2024 revenue guidance, now expecting full year 2024 revenue to in the range of $203 million to $210 million, representing growth of 5% to 9% over full year 2023, assuming no change in currency exchange rates. In addition, Cytek expects to report a net loss in the single digit millions for the full year 2024 due to an outlook of slightly lower gross profit, higher than expected stock-based compensation, and lower other income.
お知らせ • Jul 31+ 1 more updateCytek Biosciences, Inc. Automates Panel Design with New Intelligent AlgorithmCytek Biosciences, Inc. announced that it has developed a revolutionary tool to automate panel design. The company has expanded the capabilities of the Panel Builder tool within its Cytek® Cloud digital ecosystem with the addition of SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes. Optimized for Cytek’s Full Spectrum Profiling™ (FSP™) technology, the SpectroPanel tool automates the assignment of fluorochromes to markers, removing the labor-intensive manual process. This allows scientists to jumpstart their panel design process. With over 11,000 users and counting, Cytek Cloud is a vital resource in the research community. Supporting full spectrum flow cytometry research from panel design to experiment setup to data acquisition, Cytek Cloud enables researchers to design panels with ease, taking into account antigen density, marker expression, and reagent availability. Users can also access Cytek cFluor® and Tonbo™ reagents within the platform, via built-in Cytek and partner catalogs. Cytek Cloud consists of a suite of integrated, online software tools that streamline workflows – combining all spectral panel design tools in one place and allowing users to prepare experiments remotely. Cytek Cloud accelerates the time to insight for a wide range of applications, including immunology, oncology, infectious diseases, and inflammatory diseases. The Panel Builder tool features an easy-to-use panel wizard that guides panel design with the ability to search and modify pre-designed panels and Optimized Multicolor Immunofluorescence Panels (OMIPs). Users can easily build and share panels.
お知らせ • Jun 08Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The repurchase program is valid till December 31, 2024.
お知らせ • May 10Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024Cytek Biosciences reaffirms its 2024 revenue guidance, expecting full year 2024 revenue in the range of $203 million to $213 million, representing growth of 5% to 10% over full year 2023, assuming no change in currency exchange rates. For the year ending December 31, 2024, Cytek Biosciences expects to report positive net income.
お知らせ • May 01Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024Cytek Biosciences, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
お知らせ • Apr 28Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024, at 11:00 Pacific Standard Time. Agenda: To elect two Class III directors, Wenbin Jiang, Ph.D. and Michael Holder, each to serve a three-year term expiring at our 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal; to vote, on an advisory basis, regarding the compensation of named executive officers for the year ended December 31, 2023; to ratify the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.
お知らせ • Mar 19+ 1 more updateCytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development AnalyticsCytek Biosciences, Inc. announced that Patrik Jeanmonod has been appointed as the company’s head of corporate development analytics. Jeanmonod served as Cytek’s chief financial officer since 2018.
お知らせ • Mar 03Cytek Biosciences, Inc. announced delayed annual 10-K filingOn 03/01/2024, Cytek Biosciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 01Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024Cytek Biosciences, Inc. provided earnings guidance for the year ended December 31, 2024. For the period, the company expects total revenue to be in the range of $203 million to $213 million, representing growth of 5% to 10% over the year ended December 31, 2023, assuming no change in currency exchange rates. Also, the company expects to report positive net income.
お知らせ • Feb 08Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024Cytek Biosciences, Inc. announced that they will report Q4, 2023 results After-Market on Feb 28, 2024
お知らせ • Jan 08Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023Cytek Biosciences, Inc. provided revenue guidance for the year 2023. For the year, the company expects revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million, provided on November 9, 2023.
お知らせ • Dec 21Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow CytometryCytek Biosciences, Inc. announced the introduction of the Cytek Orion™ reagent cocktail preparation system. Cytek’s new automated reagent cocktailing technology simplifies and accelerates laboratory workflow, assures consistent experimental results, saves time and reduces the potential for errors. Manually preparing reagent cocktails for flow cytometry can be a time-consuming, error-prone process, particularly when panels with more than six colors are being used. The Cytek Orion system, a small, easy-to-operate, fully automated reagent cocktail preparation instrument for flow cytometry, eliminates the need for lab technicians to manually prepare multicolor antibody cocktails for flow cytometry. With the Cytek Orion system, users can mix and manage reagent cocktail combinations of up to 60 individual reagent antibody conjugates. The Cytek Orion workflow is designed to fit seamlessly with the Cytek ecosystem of complete solutions – including its cloud-based platform, analyzers, sorter, reagents, and software. It is instrument agnostic, enabling it to be used with other systems as well. Key features include: Accommodates antibody-conjugate tubes with volumes of 0.5 mL to 2.0 mL per tube, Up to 60 individual reagents can be added per cocktail, Aspirator can add 4 uL to 200 uL of reagent to cocktail at the proper volume and concentration, SpectroPrep™ software stores information regarding reagents in a library for future use and can provide an audit trail, Users can mix up to three different reagent cocktails per run, Users can create cocktail recipes and save for reuse, or use pre-programmed recipes for Cytek kits and assays. Key benefits include: Hands-on time savings in the lab due to walk away automation, Reduces costs due to potential human errors in cocktail preparation, Decrease in repetitive motion injuries when preparing high-color assays.
お知らせ • Nov 15Cytek Biosciences, Inc. announced delayed 10-Q filingOn 11/13/2023, Cytek Biosciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Nov 10Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.012 profit in 3Q 2022)Third quarter 2023 results: US$0.047 loss per share (down from US$0.012 profit in 3Q 2022). Revenue: US$48.0m (up 19% from 3Q 2022). Net loss: US$6.46m (down 488% from profit in 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 08Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023Cytek Biosciences, Inc. provided revenue guidance for the year 2023. The company expects full year 2023 total revenue to be in the range of $188 million to $192 million, representing growth of 15% to 17% over full year 2022. This includes an expected revenue contribution from organic business to be approximately flat versus 2022 and inorganic revenue in the range of $25 million to $30 million from the Luminex flow cytometry and imaging business, which was acquired on February 28, 2023.
お知らせ • Oct 20Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023Cytek Biosciences, Inc. announced that they will report Q3, 2023 results After-Market on Nov 07, 2023
New Risk • Oct 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Aug 29Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & ServicesCytek Biosciences, Inc. announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. Cytek’s acquisition of the Amnis and Guava product lines from Luminex Corporation in February 2023 provided the Company with expanded market access, new product development opportunities, and operational synergies. To take advantage of these expanded market and product development opportunities, Cytek is reorganizing its Commercial function into two distinct operations: the enhanced sales organization led by Dr. Busque, and a new Platform organization, which will encompass marketing, product roadmaps, and program management. The Company believes the new structure will support the Company’s transition toward a market-driven organization and to develop and sell cell analysis solutions based on market-derived inputs. These market inputs will shape Cytek’s research, new product, and applications development, and its approach to interacting with customers.
Reported Earnings • Aug 09Second quarter 2023 earnings released: US$0.032 loss per share (vs US$0.004 loss in 2Q 2022)Second quarter 2023 results: US$0.032 loss per share (further deteriorated from US$0.004 loss in 2Q 2022). Revenue: US$49.7m (up 24% from 2Q 2022). Net loss: US$4.39m (loss widened US$3.79m from 2Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Aug 09Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023Cytek Biosciences, Inc. provided revenue guidance for the full year 2023. For the period, the company expects total revenue to be in the range of $205 million to $220 million, representing growth of 25% to 34% over full year 2022. This includes an expected revenue contribution in the range of $180 million to $190 million from its existing organic business and in the range of $25 million to $30 million from the acquired Luminex flow cytometry and imaging business, which closed on February 28, 2023.
お知らせ • Jul 23Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023Cytek Biosciences, Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023
お知らせ • May 20Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The repurchase program will continue until the end of the fiscal year unless extended or shortened by the Board of Directors.
Reported Earnings • May 11First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.015 loss in 1Q 2022)First quarter 2023 results: US$0.05 loss per share (further deteriorated from US$0.015 loss in 1Q 2022). Revenue: US$37.1m (up 5.8% from 1Q 2022). Net loss: US$6.81m (loss widened 237% from 1Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 10Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023Cytek Biosciences, Inc. revised earnings guidance for the year 2023. The company has revised its full year 2023 revenue outlook and now expects total revenue to be in the range of $205 million to $220 million, representing growth of 25% to 34% over full year 2022. This includes an expected revenue contribution in the range of $25 million to $30 million from the acquisition of Luminex’s flow cytometry and imaging business, which closed on February 28, 2023.
Reported Earnings • Mar 02Full year 2022 earnings released: EPS: US$0.018 (vs US$0.001 in FY 2021)Full year 2022 results: EPS: US$0.018 (up from US$0.001 in FY 2021). Revenue: US$164.0m (up 28% from FY 2021). Net income: US$2.39m (up US$2.34m from FY 2021). Profit margin: 1.5% (up from 0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 14Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million.Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million on February 13, 2023. The sale is expected to close within 30 days, subject to customary closing conditions.
お知らせ • Feb 08Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023Cytek Biosciences, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 28, 2023
お知らせ • Nov 16Cytek Biosciences, Inc. Introduces Cytek CloudCytek Biosciences, Inc. announced the launch of Cytek Cloud – a cloud-based platform that features two integrated tools to streamline workflows on Cytek’s cell sorters and analyzers. Optimized for Cytek systems and reagents, Cytek Cloud joins the company’s extensive suite of solutions for the single cell analysis market, which includes the incorporation of Full Spectrum Profiling (FSP) technology onboard its flow cytometry systems, proprietary cFluor reagents, and SpectroFlo software. The new Cytek Cloud digital ecosystem combines all of Cytek’s spectral panel design tools in one place and allows users to prepare experiments remotely prior to accessing the instrument. The benefit in this approach is accelerating the time to insight for a wide range of applications including immunology, oncology, infectious diseases, and inflammatory diseases.
Reported Earnings • Nov 11Third quarter 2022 earnings released: EPS: US$0.012 (vs US$0.003 in 3Q 2021)Third quarter 2022 results: EPS: US$0.012 (up from US$0.003 in 3Q 2021). Revenue: US$40.5m (up 18% from 3Q 2021). Net income: US$1.67m (up 382% from 3Q 2021). Profit margin: 4.1% (up from 1.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 10Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022Cytek Biosciences announced that the company continues to expect full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
お知らせ • Nov 01Cytek Biosciences, Inc. Names Chris Williams Chief Operating OfficerCytek Biosciences, Inc. announced that Chris Williams has been appointed chief operating officer for the company. In this role, Williams will lead and execute the company’s global operations strategy to scale up its capability to support its mission as a full solution provider to its customers. Williams’ appointment is effective immediately, reporting directly to Dr. Wenbin Jiang, chairman and CEO of Cytek Biosciences. Prior to joining Cytek, Williams served as vice president of engineering, technology, operations and innovation for Thermo Fisher’s Pharma Services Group. Before that, he was vice president and general manager for single use technologies and vice president and general manager for bioprocess equipment and automation – both at Thermo Fisher Scientific. He also served as vice president of site engineering for Bayer Pharmaceuticals Division. Williams holds a Bachelor of Science degree in Mechanical Engineering from the University of Texas at Austin.
お知らせ • Oct 27Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022Cytek Biosciences, Inc. announced that they will report Q3, 2022 results After-Market on Nov 09, 2022
Reported Earnings • Aug 12Second quarter 2022 earnings releasedSecond quarter 2022 results: US$0.004 loss per share. Revenue: US$40.2m (up 32% from 2Q 2021). Net loss: US$598.0k (flat on 2Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 13% growth forecast for the industry in Germany.
お知らせ • Aug 11Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022Cytek Biosciences, Inc. provided earnings guidance for the full year 2022. For the period, Company expects revenue to be closer to the high end of the range of $160 million to $168 million.
お知らせ • Jul 21Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022Cytek Biosciences, Inc. announced that they will report Q2, 2022 results After-Market on Aug 10, 2022
お知らせ • Jun 26Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value IndexCytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Index
お知らせ • Jun 24Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022Cytek Biosciences, Inc. reaffirmed earning guidance for 2022. Revenue guidance closer to the higher of the range of $160 million to $168 million.
お知らせ • Jun 07Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I DirectorOn June 1, 2022, Cytek Biosciences, Inc. held its 2022 annual meeting of stockholders, elected Deborah Neff, Don Hardison as Class I director.
Reported Earnings • May 13First quarter 2022 earnings releasedFirst quarter 2022 results: US$0.015 loss per share. Revenue: US$35.1m (up 45% from 1Q 2021). Net loss: US$2.02m (flat on 1Q 2021). Over the next year, revenue is forecast to grow 29%, compared to a 13% growth forecast for the industry in Germany.
お知らせ • May 12Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022Cytek Biosciences, Inc. provided revenue guidance for the full year 2022. The company expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
お知らせ • Apr 15Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022, at 11:00 Pacific Standard Time. Agenda: To elect each of the company's two nominees, Deborah Neff and Don Hardison, to the company's board of directors for a three-year term, to hold office until the company's 2025 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal; to ratify the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2022; and to conduct any other business properly brought before the meeting.
Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: US$0.001 (down from US$0.11 in FY 2020). Revenue: US$128.0m (up 38% from FY 2020). Net income: US$52.0k (down 98% from FY 2020). Profit margin: 0% (down from 3.5% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 28%, compared to a 24% growth forecast for the pharmaceuticals industry in Germany.
お知らせ • Feb 24Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022Cytek Biosciences, Inc. provided revenue guidance for the fiscal year 2022. Cytek Biosciences expects full year 2022 revenue to be in the range of $160 million to $168 million.
お知らせ • Feb 12Cytek Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022Cytek Biosciences, Inc. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022
